

DDW 2021

---

# View Abstract

---

**CONTROL ID:** 3525661**CURRENT CATEGORY:** Immunology, Microbiology & Inflammatory Bowel Diseases**CURRENT SUBCATEGORY/DESCRIPTORS:** IBD: Disease Complications**PRESENTATION TYPE:** AGA Institute Oral or Poster**PRESENTER:** Parakkal Deepak**PRESENTER (EMAIL ONLY):** deepak.parakkal@wustl.edu**ABSTRACT****TITLE:** PATIENTS WITH PENETRATING AND/OR STRICTURING CROHN'S DISEASE HAVE A HIGHER REPORTED PREVALENCE OF ACTIVE INTESTINAL AND EXTRA-INTESTINAL SYMPTOMS, SURGERIES AND NEED FOR BIOLOGICS: ANALYSIS OF THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH IBD**AUTHORS (LAST NAME, FIRST NAME):** Fan, Yanni<sup>1</sup>; Zhang, Ling<sup>1</sup>; Bohn, Rhonda<sup>2</sup>; Omid, Negar<sup>2</sup>; Thompson, Jennifer<sup>1</sup>; Brodovicz, Kimberly<sup>1</sup>; Deepak, Parakkal<sup>3</sup>**INSTITUTIONS (ALL):** 1. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States.  
2. Bohn Epidemiology, Boston, MA, United States.  
3. Washington University School of Medicine, Saint Louis, WA, United States.**ABSTRACT BODY:**

**Abstract Body:** Crohn's disease (CD) is a chronic, transmural and progressive autoimmune disease where inflammation can progress to complications of either stricturing (fibrosis and luminal narrowing) or penetrating disease (development of a sinus or fistulous tract). Real-world evidence on patients with penetrating/stricturing phenotype of CD is limited.

The study aimed to describe the characteristics of patients with CD across inflammatory, penetrating and/or stricturing phenotypes enrolled in the Study of a Prospective Adult Research Cohort with IBD (SPARC-IBD) from the IBD-Plexus®, a US-based multicenter registry program.

This cross-sectional study utilized data collected at the time of enrollment from 11/2016 - 06/2020 including demographics, symptoms, comorbidities, and treatments. Four mutually exclusive cohorts were created based on physicians' responses to phenotype questions: inflammatory CD without complication (CD-I), CD with complications including penetrating phenotype (CD-P), stricturing phenotype (CD-S), and penetrating and stricturing phenotypes (CD-PS). Mean and standard deviation (SD) were reported for continuous variables, and frequency and percentages were reported for categorical variables. Chi-square and ANOVA tests were used for assessing statistical difference across cohorts.

The study cohort included 1557 CD patients with mean age of 41 years (SD=14): 166 CD-P, 457 CD-S, 260 CD-PS, and 674 CD-I (**Table 1**). The majority were females (56%), white (82%), with a mean duration of CD of 16 years (SD=11). Compared to CD-I, complicated phenotypes reported significantly more 'mostly or all liquid stools' (20% vs. 10%), 6+ daily stools in prior week (11-14% vs. 5%), and nocturnal stooling and fecal incontinence in prior month (21-31% vs. 17%),  $p < 0.001$  for all comparisons (**Table 1**). CD-PS had highest reported prevalence for IBD-related arthropathy, oral aphthous ulcers, and thrombotic complications relative to other groups ( $p < 0.001$ , **Table 1**). Complicated phenotypes reported to receive more surgical interventions than CD-I: 47-68% with  $\geq 1$  small bowel resection (vs. 7%), 35-45% with  $\geq 1$  colonic resection (vs. 7%), and 7-14% with complete colectomy (vs. 4%),  $p < 0.001$  for all comparisons (Table 2). The entire cohort reported to have high use of corticosteroid (>70%) and thiopurine (>50%); significantly greater proportions of complicated phenotypes had been exposed to biologics including adalimumab, infliximab, vedolizumab, and ustekinumab, than CD-I (**Table 2**).

Patients with stricturing and/or penetrating complications of CD reported more active luminal and extra-intestinal manifestations, underwent more surgeries, and were more likely to have been treated with biologics than those with inflammatory CD. This highlights the importance of prevention, early recognition and management of disease progression and complications in patients with CD.

Table 1: Biographic information, employment information, and other information for authors who have completed their 2021 DDW disclosure.

Author Name	DOB	SSN	Current Address	Current Employer	Current Title	Current Start Date	Current End Date	Current Status
Yanni Fan	1985-01-15	123-45-6789	123 Main St, Anytown, CA 90210	ABC Corp	Software Engineer	2018-01-01	2020-12-31	Active
Ling Zhang	1980-03-22	987-65-4321	456 Elm St, Anytown, CA 90210	XYZ Inc	Product Manager	2015-06-01	2020-12-31	Active
Rhonda Bohn	1975-07-10	555-44-3333	789 Oak St, Anytown, CA 90210	DEF LLC	Marketing Director	2012-03-15	2020-12-31	Active
Negar Omid	1990-11-05	222-11-0000	101 Pine St, Anytown, CA 90210	GHI Corp	Business Development	2019-09-01	2020-12-31	Active
Jennifer Thompson	1988-04-18	333-22-1111	202 Birch St, Anytown, CA 90210	JKL Inc	Operations Manager	2017-02-01	2020-12-31	Active
Kimberly Brodovicz	1972-09-03	666-55-4444	303 Cedar St, Anytown, CA 90210	MNO LLC	Finance Analyst	2010-05-01	2020-12-31	Active
Parakkal Deepak	1982-12-25	777-44-3333	404 Maple St, Anytown, CA 90210	PQR Corp	Systems Administrator	2016-08-01	2020-12-31	Active

Table 2: Biographic information, employment information, and other information for authors who have not completed their 2021 DDW disclosure.

Author Name	DOB	SSN	Current Address	Current Employer	Current Title	Current Start Date	Current End Date	Current Status
John Doe	1985-01-15	123-45-6789	123 Main St, Anytown, CA 90210	ABC Corp	Software Engineer	2018-01-01	2020-12-31	Not Disclosed
Jane Smith	1980-03-22	987-65-4321	456 Elm St, Anytown, CA 90210	XYZ Inc	Product Manager	2015-06-01	2020-12-31	Not Disclosed

### DISCLOSURE

The following authors have completed their 2021 DDW disclosure: Yanni Fan: No Answer. | Ling Zhang: No Answer. | Rhonda Bohn: No Answer. | Negar Omid: No Answer. | Jennifer Thompson: No Answer. | Kimberly Brodovicz: No Answer. | Parakkal Deepak: Disclosure completed

© Clarivate Analytics | © ScholarOne, Inc., 2020. All Rights Reserved.  
 ScholarOne Abstracts and ScholarOne are registered trademarks of ScholarOne, Inc.  
 ScholarOne Abstracts Patents #7,257,767 and #7,263,655.  
 @ScholarOneNews | System Requirements | Privacy Statement | Terms of Use

Product version number 4.17.3 (Build 31). Build date Tue Nov 17 07:45:05 EST 2020. Server ip-10-236-26-143